SEQLL, which provides a genetic sequencing platform for researching the makeup of diseases, announced terms for its IPO on Tuesday.
The Woburn, MA-based company plans to raise $8 million by offering 1.4 million shares at a price range of $5.40 to $6.40. At the midpoint of the proposed range, SEQLL would command a fully diluted market value of $63 million.
SEQLL was founded in 2013 and booked $1 million in sales for the 12 months ended December 31, 2018. It plans to list on the Nasdaq under the symbol SQL. WallachBeth Capital is the sole bookrunner on the deal.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.